HINJ and New Jersey's Life Sciences Community Brochure

Download HINJ and New Jersey’s Life Sciences Community


To learn more about our
Life Sciences industry,




On the Move! HINJ to Relocate Offices in Same New Brunswick Complex on April 27

On Thursday, April 27, HINJ will relocate offices.  However, HINJ is not moving far — in fact, it is moving from one tower and suite to another in the same office complex in New Brunswick.

HINJ’s new location will be: 120 Albany Street, Tower Two, Suite 350, New Brunswick, NJ 08901.

Everything else — including our phone and fax numbers — will remain unchanged.

Because of the move, HINJ will be “off the grid” — in terms of email and land-line phone service — for most of the work day on Thursday.  

If you need to contact HINJ on April 27, please contact HINJ Director of Communications Doug Berger at 212-262-1168 (cell).

HINJ Partners to Host ‘NJ Rare Disease Day 2017’ on February 27

New Jersey’s rare disease community will gather to celebrate Rare Disease Day 2017 on Monday, February 27 from 9:00 a.m. to 12:00 p.m. at the New Jersey Business and Industry Association (NJBIA) at 10 West Lafayette Street in Trenton.

The half-day event will be co-sponsored by BioNJ, HINJ, New Jersey Rare Disease Alliance and NORD.

The event will feature speakers from the rare disease community, including patients, patient advocates, legislators, biomedical healthcare professionals and life sciences leaders.

To register, please click here.

For the complete story, please click here.


HINJ, BioNJ and NJ Tech Council Partner on NJEDA’s ‘Early Stage Biotech Investing in 2017’ Strategies Forum on January 17

 HINJ, BioNJ and the NJ Tech Council are partnering with the New Jersey Economic Development Authority (NJEDA) to present “Early Stage Biotech Investing in 2017: Strategies for a Changing Environment.”

The forum will be held on Tuesday, January 17 from 4:30 to 6:30 p.m. at the Commercialization Center for Innovative Technologies (CCIT), a life sciences incubator, at 675 US Highway One, North Brunswick.

To register, please click here.

For the complete story, please click here.

HINJ to Co-Sponsor Rutgers-Industry Cancer Research Symposium on January 24

HINJ is pleased to co-sponsor a Rutgers-Industry Cancer Symposium that will be presented on Tuesday, January 24 from 4:00 to 6:00 p.m. in Auditorium A and B at the Rutgers Cancer Institute of New Jersey at 195 Little Albany Street, New Brunswick. 

This series is designed to foster collaboration and networking between Rutgers faculty and strategic industry partners. 

At the January 24 symposium, Rutgers researchers will present an update on clinical investigations. In addition, Incyte Corporation will present an update on drugs in its pipeline. 

Registration is not required.  For the event flyer, click here.

HINJ Congratulates Congressman Frelinghuysen on Becoming Chairman of House Appropriations Committee

Chairman Rodney Frelinghuysen

Chairman Rodney Frelinghuysen

HINJ on December 2 extended our sincere congratulations to New Jersey Congressman Rodney P. Frelinghuysen (R-11) on his election as Chairman of the House Appropriations Committee.

“Chairman Frelinghuysen is a true public servant who has dedicated his career to the betterment of his constituents, our great state of New Jersey and our nation,” said Dean J. Paranicas, HINJ President and Chief Executive Officer.  “Being selected by his House colleagues to chair one of the most influential committees in federal government is a testament to his informed approach to public policy and his leadership qualities.”

“This is an exciting and historic opportunity for New Jersey to have one of our own federal legislators be recognized in such a prominent way for his longstanding commitment to America’s critical priorities,” Paranicas continued.  “Mr. Frelinghuysen’s tenure as Appropriations Chairman will undoubtedly benefit our country greatly.  We wish him much success and look forward to working with him in his new role.”

HINJ Launches STEM Education Portal; Focus Is on Life Sciences’ Investment in Tomorrow’s Innovation Leaders

stem-1HINJ has launched a STEM Education portal that focuses on the life sciences community’s investment in today’s science, technology, engineering and mathematics (STEM) educators and students, who will become tomorrow’s innovation leaders.

HINJ’s new STEM Education portal presents information from a number of sources regarding the current state of STEM education in the U.S., its significance to the nation’s and New Jersey’s economic well-being, its importance to advancing medical innovation, and the life sciences industry’ investment in programs designed to advance STEM education.

The STEM Education page is the latest offering on HINJ.org, which was re-launched in February 2013.

For the complete story, please click here.


HINJ 2016 Life Sciences Celebration, honors Public Service, Research, Patient Advocacy and Education Contributions

(L. to r.) (L. to r.) HINJ Board Chair Jeff Sherman (BD), HINJ Steering Committee Chair Wendy Lazarus (Pfizer), Warren Moore, Amy Mansue, Assemblyman Herb Conaway, Jr., Dr. Michael Christman, Dr. Barry Komisaruk and Dean J. Paranicas

(L. to r.) HINJ Board Chair Jeff Sherman (BD); HINJ Steering Committee Chair Wendy Lazarus (Pfizer); Warren Moore; Amy Mansue; Assemblyman Herb Conaway, Jr., M.D.; Michael Christman, Ph.D.; Barry Komisaruk, Ph.D.; and HINJ President and CEO Dean J. Paranicas

HINJ on October 6 honored five individuals and one organization for their contributions in public service, medical sciences research, patient access/advocacy and education.  HINJ’s 2016 honorees were:

  • The Honorable Bob Franks Public Service Award: The Honorable Herb Conaway, Jr., M.D., Member, New Jersey General Assembly, Chair, Health and Senior Services Committee
  • Research: Michael F. Christman, Ph.D., President and CEO, Coriell Institute for Medical Research
  • Patient Advocacy: Children’s Specialized Hospital; Amy B. Mansue, President, Southern Region, RWJBarnabas Health, and Warren E. Moore, President and CEO
  • Special Recognition: Barry R. Komisaruk, Ph.D., Distinguished Professor of Psychology, Rutgers University Board of Governors Distinguished Service Professor, Director, NIH-Minority Biomedical Research Support Program at Rutgers-Newark

To learn more about the annual HINJ Life Science Celebration — including about past HINJ honorees — please visit HINJ Life Sciences Celebration page.

Celebration photos have been posted on Facebook.

For the complete story, please click here.

NJ Spotlight Publishes Op-Ed by HINJ, Colleague Organizations on ‘New Jersey’s Universities Are Key to Innovation and the State’s Prosperity’nj-spotlight

NJ Spotlight published on October 3 an op-ed by Dean J. Paranicas, HINJ President and CEO; James Barrood, president and CEO, New Jersey Technology Council; Thomas A. Bracken, president and CEO, New Jersey Chamber of Commerce, Anthony S. Cicatiello, president, The Research & Development Council of New Jersey; Debbie Hart, president and CEO, BioNJ; and Michele N. Siekerka, president and CEO, New Jersey Business & Industry Association. 

They concluded:

“The research capabilities of New Jersey’s universities are essential to the vitality of our own innovation ecosystem and ability to continue to compete effectively against these locales.  It’s therefore hard to envision that an outcome inconsistent with this objective would be a desired public policy for the state.

“Instead, for New Jersey to keep pace, we need a sustained, broad-based commitment to our universities as key engines of global innovation and state economic development.  The future of our state’s economy depends on it.” 

For the complete op-ed, please click here.

HINJ Announces New Board and Steering Committee Leadership; BD’s Jeffrey Sherman Named Board Chair

Jeffrey S. Sherman

Jeffrey S. Sherman

Jeffrey S. Sherman, Executive Vice President and General Counsel, BD (Becton, Dickinson and Company), has been named Chair of the HINJ Board of Trustees.  He previously served as Treasurer of the HINJ Board.

Mr. Sherman succeeds Craig B. Bleifer, Vice President, General Counsel and Secretary, Daiichi Sankyo, Inc.  Mr. Bleifer continues to serve the HINJ Board as its Treasurer.

The HINJ Board elected two Vice Chairs: Yin C. Becker, Vice President, Communications and Public Affairs, Stryker, and Mark J. Alles, Chief Executive Officer, Celgene Corporation

HINJ also announced that Wendy M. Lazarus, Director, State Government Relations, Pfizer Inc., will continue to serve as the Chair of the HINJ Steering Committee.  Todd Spangler, Director, Public Policy & Government Relations, BD, will serve as Vice Chair.

For the complete story, please click here.

New Jersey to Showcase Its Life Sciences Leadership at BIO International 2016BIO Pavilion 2016 Booth

New Jersey will showcase more than 20 organizations, including top companies, universities, trade associations, State government and Choose New Jersey, Inc. at the New Jersey Pavilion (Booth #6544, North Exhibition Hall) at Bio International 2016, the world’s largest biotechnology conference.

From June 7-9, the New Jersey delegation — including HINJ — will meet with European, Canadian and Australian business executives from life science-based organizations interested in learning what makes the State a perfect place to start or relocate their bio-related firm.

HINJ is the lead sponsor of Choose New Jersey’s reception on Tuesday evening at which guests will learn of the strategic advantages of a New Jersey location for their life sciences companies.

For the complete story, please click here.

HINJ and Other New Jersey Healthcare Leaders Hold Summit on Key Challenges

(L. to r.)  HINJ's Dean Paranicas, MSNJ's Larry Downs, NJAHP's Ward Sanders and NJHA's Betsy Ryan

(L. to r.) HINJ’s Dean Paranicas, MSNJ’s Larry Downs, NJAHP’s Wardell Sanders and NJHA’s Elizabeth Ryan

Members of the state’s various healthcare communities — hospitals, health plans, physicians and life sciences — gathered for the New Jersey Healthcare Stakeholders Summit on April 21 for a daylong event to discuss the key challenges facing the healthcare delivery system.

The event was a joint effort of HINJ, the Medical Society of New Jersey (MSNJ), the New Jersey Association of Health Plans (NJAHP) and the New Jersey Hospital Association (NJHA)

HINJ President and Chief Executive Officer Dean Paranicas said, “Our healthcare ecosystem is comprised of different sectors, each with its unique perspective and focus that sometimes produces shared and other times divergent views on healthcare issues.  However, all of these sectors are focused on the same goal: helping patients.”

“Today’s event,” Paranicas continued, “demonstrates a collaborative approach to exploring new ways of working together to benefit patients and our entire healthcare system in aggregate.”

For the complete story, please click here.


PharmFest at Montclair University

PharmFest 2016, a biennial forum presented by Montclair State University in partnership with HINJ, was held on Wednesday, April 13 at the MSU’s Conference Center. 

With the theme of “The Value of Innovation,” PharmFest 2016 explored emerging issues and trends impacting the biopharmaceutical, health and medical technology sectors and to broaden awareness of the current and future state of the industry. 

John Crowley, Chairman and CEO, Amicus Therapeutics, Inc., and Brian Gragnolati, President and CEO, Atlantic Health Systems, keynoted.  

HINJ’S ‘By the Numbers’ Portal Showcases Life Sciences’ NEW JERSEY Economic Impact

Economic Development 2HINJ has updated “New Jersey Life Sciences: By the Numbers,” the association’s compilation of information from HINJ and third-party sources on the life sciences sector’s significant impact on New Jersey’s economy.

HINJ’s By the Numbers includes economic-impact data from a number of resources, including the New Jersey Department of Labor & Workforce Development, the Food and Drug Administration, the Biotechnology Innovation Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA), Choose New Jersey and We Work for Health New Jersey, among others.

HINJ’s expanded By the Number page is the latest offering on HINJ.org, which was relaunched in February 2013 as part of HINJ’s strategic plan to build a dynamic communications capability that delivers relevant, robust and timely information to internal and external stakeholders.

For the complete story, please click here.

HINJ Co-SponsorS Rare Disease Day 2016; Focus on Building Relationships, Raising Awareness in Trenton

Rare Disease Day

HINJ partnered with the New Jersey Rare Disease Alliance (NJRDA) on its activities to recognize Rare Disease Day 2016 on February 29 at the New Jersey Business and Industry Association (NJBIA) in Trenton.

The half-day event was also co-sponsored by BioNJ and the National Organization for Rare Diseases (NORD).

Speaking at the event, HINJ President and Chief Executive Officer Dean J. Paranicas emphasized the importance of a collaborative effort in building relationships with, and educating, policymakers, both in Trenton and Washington, DC.

For the complete story, click here.

HINJ’s Berman Named to Chair NJBIA’s Innovation and Technology Committee

Innovation button touch 2

HINJ Senior Vice President – State Affairs Haskell Berman has been named as chair of New Jersey Business & Industry Association (NJBIA) newly created Innovation and Technology Policy Committee.

The committee will develop and advocate for policies that promote investment in research and development, collaboration between industry and higher education institutions, and entrepreneurship that will proliferate New Jersey’s standing as a global research hub and retain the economic benefits on which the state has come to rely.

The committee will complement the work of Innovation New Jersey, a coalition that was co-founded in 2010 by HINJ and NJBIA.

For the complete story, click here.

HINJ Statement on Passage of the Omnibus Spending Package

Capitol Building flag

HINJ on December 18 congratulated Congress on the passage of legislation that includes several key provisions that will strengthen medical innovation in the United States. 

The spending measure, which received bipartisan support, includes $2 billion in increased funding for the National Institutes of Health (NIH); a $133 million increase in funding for the Food and Drug Administration (FDA); a two-year suspension of the medical device excise tax; and makes permanent the Research & Development (R&D) tax credit.

HINJ President and Chief Executive Officer Dean J. Paranicas said, “We are grateful to New Jersey’s Congressional Delegation for their significant work on these important provisions that foster the innovation environment to research and discover the next generation of treatments and cures.”

“This legislation will greatly benefit patients awaiting advances in medical care, improves global human health, and strengthens New Jersey’s innovative ecosystem and jobs,” Paranicas continued.  “We look forward to its enactment.”

HINJ, Rx4NJ and WWFH-NJ Host ‘The Value of Medical Innovation: Saving Lives, Saving Money’ Policy Forum

Dean Paranicas and PhRMA’s Dr. Michael Ybarra

HINJ, the Rx4NJ Partnership and We Work for Health New Jersey (WWFH-NJ) hosted a health policy forum on December 15 that focused on “The Value of Medical Innovation: Saving Lives, Saving Money.”  Speakers were:

Dr. Ybarra and Paranicas presented a fact-driven presentation of PhRMA’s “Prescription Medicines:  Costs in Context.”

For the complete story, click here.

NJTV News Explores Prescription Drug Prices in the U.S.; HINJ CEO Dean Paranicas Interviewed

NJTV News w Mary Alice Williams

In a segment broadcast on December 4, NJTV News explored prescription drug prices in the U.S. and consumer concerns.

HINJ President and Chief Executive Officer Dean J. Paranicas told correspondent Erin Delmore, “So much of the cost of those drugs is offset by rebates, discounts, coupons and the like, in terms of what the true cost of the drug is.”

Paranicas pointed out that medication costs include the price of innovation.  “Drug development is an incredibly expensive, incredibly risky, incredibly lengthy process,” he said.

“The typical prescription drug takes on average $2.6 billion and 12 to 15 years to develop,” Paranicas said.  “Now, that just represents the drug that actually succeeds in getting into the marketplace.  Only about 12 percent of the drug candidates that even get into clinical trials are ultimately approved by the FDA.” 

To read the complete story, click here.  To view the NJTV News segment, click here.

HINJ and NJ Life Sciences Vendors Alliance Host 2015 Procurement Conference


HINJ and the New Jersey Life Sciences Vendors Alliance’s (NJLSVA) hosted the 2015 Annual Procurement Conference on November 11 at Forsgate Country Club in Cranbury, New Jersey

Co-sponsored by the MID Jersey Chamber of Commerce, speakers at the half-day event were:

  • David McCarthy, Senior Director, PGS Procurement – Americas, Pfizer, Inc.
  • Patrick Murray, Director, Monmouth University Polling Institute
  • The Honorable Declan O’Scanlon, Republican Budget Officer, New Jersey General Assembly
  • Dean J. Paranicas, President and Chief Executive Officer, HINJ
  • The Honorable Bob Prunetti, President, MID Jersey Chamber of Commerce
  • Donald Sico, Executive Director, NJLSVA

For the complete story, click here.

HINJ Honors Four at Life Sciences Celebration 2015: Rep. Lance, Dr. Nils Lonberg, Deborah Brown, David Knowlton

(L. to r.) HINJ President and CEO Dean Paranicas, Deborah Brown, Scott Knowlton, Rep. Leonard Lance, Dr. Nils Lonberg and HINJ Chair Craig Bleifer

(L. to r.) HINJ President and CEO Dean Paranicas, Deborah Brown, Scott Knowlton, Rep. Leonard Lance, Dr. Nils Lonberg and HINJ Chair Craig Bleifer

HINJ honored meritorious leadership in and contributions to New Jersey’s life sciences community at its 2015 Life Sciences Celebration, which was held October 30 at the Wyndham Garden Trenton.

HINJ’s 2015 honorees were:

  • The Honorable Bob Franks Public Service Award: Leonard Lance (R-7), Member, US House Energy and Commerce Committee
  • Research: Nils Lonberg, Ph.D., Senior Vice President, Oncology Discovery Biology, Bristol-Myers Squibb Company
  • Patient Advocacy: Deborah P. Brown, President and Chief Executive Officer, American Lung Association of the Mid-Atlantic
  • Special Recognition: David L. Knowlton, President and Chief Executive Officer, New Jersey Health Care Quality Institute

For the complete story, click here.

HINJ Launches ‘Value of Medical Innovation’ Website Section; Focuses on Saving Lives — And Saving MoneYInnovation value of medical innovation

HINJ has updated its online portal at HINJ.org to present Value of Medical Innovation, a fact-driven, consumer-friendly digital library that delves into the myriad benefits of medical innovation, which saves lives — and saves money.

HINJ’s Value of Medical Innovation presents statistics from a number of resources, including the U.S. government, AdvaMed, BIO, PhRMA and various medical research organizations.

In November 2014, HINJ added a Corporate Social Responsibility section to its website that focuses on HINJ member companies’ Corporate Social Responsibility (CSR) activities.

To visit HINJ’s newest online offering, click on the Value of Medical Innovation tab at the top of this page or click here.

For the complete story, click here.


HINJ Updates Portal of Member Companies’ Corporate Social Responsibility and Sustainability Activities

CSR chasing arrows

HINJ has updated its online portal to HINJ member companies’ myriad corporate social responsibility (CSR) activities, including their corporate philanthropy, patient outreach initiatives and sustainability/green practices

Launched in November 2014 and promoted via Twitter, Facebook and LinkedIn, HINJ’s CSR online portal has become one of the most-visited areas of our website

The portal — “HINJ Members’ CSR Activities” — is accessible by clicking on the second tab under the HINJ homepage’s Corporate Social Responsibility menu

For the complete story, click here.



Dean J. Paranicas -- HINJ President & Chief Executive Officer (low-res)

Dean J. Paranicas, President and Chief Executive Officer, HINJ

NJ Spotlight has published an op-ed authored by HINJ President and Chief Executive Officer Dean Paranicas on the subject of patent reform legislation currently pending before the U.S. House of Representatives.  Paranicas writes:

[Life sciences companies] depend on a strong, robust patent system to protect the intellectual property needed to discover these treatments and cures. 

“In 2011, Congress passed, with bipartisan support, the America Invents Act (AIA) …. However, the implementation of specific provisions of the AIA has unintentionally — and unfairly — put patent holders at a disadvantage. …

“Life-sciences companies support efforts to curb the abusive practices of patent trolls, and we will work with Congress to craft legislation that strikes the right balance without undermining the ability of legitimate patent holders to enforce their rights.”

To read Paranicas’ complete op-ed piece, click here.


Video ChooseNJ 20150618

HINJ President and Chief Executive Officer Dean J. Paranicas was one of the state leaders included in Choose New Jersey’s new video — “Leaders Choose New Jersey: Highly Educated, Perfectly Located” — that premiered at the 2015 BIO International Convention, which was held June 15-18 in Philadelphia.

Other New Jersey leaders appearing in the video to promote the state as a winning place for life sciences companies to invest are Governor Chris Christie, Lt. Governor Kim Guadagno, Michele Brown of ChooseNJ, Aaron Graff of Ferring Pharmaceuticals, Debbie Hart of BioNJ, Dr. Chris Molloy of Rutgers University, and Dr. Jay Tischfield of RUCDR Infinite Biologics.

To view the 4:17-minute video, click here

For the complete story, click here.



HINJ’s Dean Paranicas (l.) and  Congressman Leonard Lance

HINJ President and CEO Dean Paranicas was a guest on Rep. Leonard Lance’s (R-7) “Seventh District Congressional Report,” which will be broadcast on various public broadcast stations in the coming days.

Rep. Lance and Paranicas focused on the life sciences’ impact on the state’s economy; the FDA Safety Over Sequestration (SOS) Act, which seeks to exempt FDA user fees from sequestration; and the 21st Century Cures initiative.

For the full story, click here.


Password Reset

Please enter your e-mail address. You will receive a new password via e-mail.